Novel mRNA Cancer Vaccine Shows Promise in Reducing Melanoma Recurrence

A personalized mRNA cancer vaccine is significantly reducing the chances of melanoma tumors returning in patients, according to results from a large-scale study released by drugmakers Moderna and Merck. The custom-brewed vaccine, designed to target unique mutations within each patient's tumor, when added to standard post-surgery treatment, decreased the risk of melanoma recurrence by 42% two years after surgery.

This development marks a significant advancement in cancer treatment, utilizing the same Nobel Prize-winning mRNA technology that underpinned COVID-19 vaccines. Experts not involved in the study have hailed it as a major step forward for oncology and a new frontier in cancer immunotherapy.

Study Details and Mechanism

The international study involved over 1,100 participants with high-risk melanoma that had been surgically removed. All participants received Merck's immunotherapy drug Keytruda as standard follow-up treatment. Participants were then randomly assigned to either receive the custom-made mRNA vaccine or a placebo. The vaccine, named intisomeran, involves nine doses administered three weeks apart. It works by teaching the patient's immune system to identify and attack specific proteins, known as neoantigens, that are produced by cancer cells and signal their potential return.

Outcomes and Patient Experience

Two years post-surgery, 82% of patients who received the vaccine alongside Keytruda were alive and cancer-free, compared to 70% of those who received Keytruda alone. The trial continues to monitor long-term outcomes. One participant, Tony Hout, joined the trial after his melanoma was found to have spread following surgery. He expressed a desire to "make sure I'm doing everything I can to be here for my family" and reported being cancer-free in recent check-ups.

Side Effects and Future Steps

The vaccine's side effects were reported to be similar to those experienced with mRNA COVID-19 vaccinations, primarily a sore arm, fatigue, and other typical reactions. Moderna and Merck are currently in discussions with regulatory authorities regarding the next steps for seeking approval for the vaccine. The cost of such personalized medicines has not yet been discussed, but Moderna has indicated its manufacturing facility is producing doses for thousands of participants in ongoing studies.

The process for creating the vaccine involves analyzing tumor genetics to develop a unique recipe for each patient, a procedure that can take approximately six weeks. While this process is underway, melanoma patients begin their standard Keytruda treatment. Moderna's shares saw a notable drop following the full release of the study's detailed results, although they remain significantly higher than before initial positive findings were announced in late August.